All Insurance Policy Changes (Page 1168)

Continuing from page 1167. Showing older policy changes tracked across all payers. Use the filters in the related-hubs section below to narrow by provider, state, or specialty.

Medium impact
09.00.24c, Full-Body Computerized Tomography (CT) Scan Screening
Independence Blue Cross·Effective Oct 1, 2025
Commercial insurance policy 09.00.24c for Full-Body CT Scan Screening has been reissued with an effective date of October 1, 2025. This appears to be a policy update that will impact billing and coverage for full-body CT screening procedures.
Medium impact
07.03.15d, Evaluation and Management (E&M) of Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS)
Independence Blue Cross·Effective Oct 1, 2025
Policy 07.03.15d has been reissued effective 10/01/2025 for evaluation and management of diabetic peripheral neuropathy with loss of protective sensation. However, the specific policy content is not provided in the source material, only the title, effective date, and URL. The billing team cannot determine what changed, which codes are affected, or what actions are required without access to the full policy text and any prior version for comparison.
Low impact
11.08.05g, Application and Removal of Tattoos
Independence Blue Cross·Effective Oct 1, 2025
The tattoo application and removal medical policy (11.08.05g) has been reissued with updates effective October 1, 2025. This policy governs coverage criteria and billing requirements for tattoo-related procedures under commercial insurance plans.
Medium impact
11.05.07d, Surgical Correction of Strabismus
Independence Blue Cross·Effective Oct 1, 2025
The surgical correction of strabismus medical policy (11.05.07d) has been reissued for commercial plans. This appears to be a routine policy reissuance without specific changes detailed in the summary provided.
Low impact
07.13.07l, Corneal Pachymetry Using Ultrasound
Independence Blue Cross·Effective Oct 1, 2025
The Corneal Pachymetry Using Ultrasound medical policy (07.13.07l) has been reissued for commercial insurance plans. This appears to be a routine policy reissuance without substantive changes to coverage or billing requirements.
Low impact
09.00.51a, Positron Emission Mammography (PEM)
Independence Blue Cross·Effective Oct 1, 2025
Independence Blue Cross has reissued their Positron Emission Mammography (PEM) policy effective October 1, 2025. This is a reissue of an existing policy rather than a substantive change to coverage or billing requirements.
Medium impact
11.06.06h, Magnetic Resonance Imaging (MRI)-Guided Focused Ultrasound Ablation
Independence Blue Cross·Effective Oct 1, 2025
Independence Blue Cross has reissued policy 11.06.06h covering MRI-Guided Focused Ultrasound Ablation procedures. This is a commercial policy reissue that took effect October 1, 2025, but specific coverage or billing changes are not detailed in the summary provided.
Medium impact
12.04.04b, Acute Care Facility Inpatient Transfers
Independence Blue Cross·Effective Oct 1, 2025
This is a reissued policy update regarding acute care facility inpatient transfers for commercial insurance plans. The policy has been reposted with an effective date of October 1, 2025, but specific changes are not detailed in the summary provided.
Medium impact
05.00.47u, Knee Orthoses
Independence Blue Cross·Effective Oct 1, 2025
Policy 05.00.47u for Knee Orthoses has been reissued effective October 1, 2025. This is a summary-only update with no detailed content provided about specific changes to coverage, billing, or authorization requirements for knee braces and orthotic devices.
Medium impact
05.00.39v, Ankle-Foot/Knee-Ankle-Foot Orthoses
Independence Blue Cross·Effective Oct 1, 2025
Independence Blue Cross has reissued policy 05.00.39v covering Ankle-Foot and Knee-Ankle-Foot Orthoses, effective October 1, 2025. This is a reissuance of existing policy rather than new coverage changes, but the updated version may contain modified coverage criteria or documentation requirements.
Medium impact
11.14.21l, Microprocessor-Controlled Prostheses for Lower-Extremity Amputees
Independence Blue Cross·Effective Oct 1, 2025
This is a reissued policy regarding coverage for microprocessor-controlled prostheses for lower-extremity amputees under commercial plans. The policy was reposted on 10/01/2025 with the same effective date, suggesting clarifications or corrections to the original policy without substantive changes to coverage or billing requirements.
Medium impact
05.00.11l, Therapeutic Shoes and Orthopedic Shoes
Independence Blue Cross·Effective Nov 1, 2025
Policy 05.00.11l regarding Therapeutic Shoes and Orthopedic Shoes has been updated effective November 1, 2025. This recent change (posted October 31, 2025) involves updates to medical necessity criteria and general description/guidelines. The billing team must review the full policy content to identify specific changes to coverage requirements, documentation standards, or billing procedures for therapeutic and orthopedic shoe claims.
Medium impact
08.01.13l, Brentuximab Vedotin (Adcetris®)
Independence Blue Cross·Effective Oct 20, 2025
Policy 08.01.13l updates medical necessity criteria, medical coding guidelines, and general informational content for Brentuximab Vedotin (Adcetris®), effective October 20, 2025. The billing team must review updated authorization requirements and coding standards to ensure compliant claim submission for this specialty oncology drug.
Medium impact
07.07.03n, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])
Independence Blue Cross·Effective Oct 20, 2025
Policy 07.07.03n has been updated as a medical coding and informational update effective October 20, 2025. This recent policy change affects photodynamic therapy (PDT) billing using Levulan® Kerastick® or Ameluz® (aminolevulinic acid HCl). The billing team must review the updated guidance to ensure accurate coding and compliance with current requirements.
Medium impact
07.05.02t, Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders
Independence Blue Cross·Effective Oct 20, 2025
Policy 07.05.02t has been updated with changes to medical necessity criteria and general guidelines for wireless capsule endoscopy in gastrointestinal disorders. The billing team must review updated coverage requirements and apply new medical necessity standards to all wireless capsule endoscopy claims effective immediately.
Medium impact
08.01.21h, Blinatumomab (Blincyto®)
Independence Blue Cross·Effective Oct 20, 2025
Policy 08.01.21h for Blinatumomab (Blincyto®) has been updated effective October 20, 2025, with changes to medical necessity criteria, medical coding, and general guidelines. The billing team must review updated coverage requirements and coding guidance to ensure compliant claim submission for this specialty pharmaceutical agent.
Low impact
07.00.21k, Allergy Immunotherapy
Independence Blue Cross·Effective Oct 20, 2025
Independence Blue Cross updated their commercial medical policy for Allergy Immunotherapy (Policy 07.00.21k). This appears to be a general informational update to the policy guidelines rather than a significant coverage or billing requirement change.
High impact
11.07.01ac, Hematopoietic Stem Cell Transplantation
Independence Blue Cross·Effective Oct 20, 2025
Independence Blue Cross updated their medical necessity criteria for Hematopoietic Stem Cell Transplantation procedures. This change affects coverage determinations and approval requirements for stem cell transplant services under commercial insurance plans.
Medium impact
12.04.03d, Air Ambulance Services
Independence Blue Cross·Effective Oct 6, 2025
Policy 12.04.03d has been updated with new medical necessity criteria for air ambulance services, effective October 6, 2025. The billing team must implement updated authorization and documentation requirements to ensure claims comply with the revised criteria and avoid denials.
Medium impact
12.04.02l, Ground Ambulance Services (Emergency and Nonemergency) (Independence)
Independence Blue Cross·Effective Oct 6, 2025
Independence insurance has updated medical necessity criteria for ground ambulance services (both emergency and nonemergency). This is a recent policy change effective October 6, 2025, that may affect how claims are evaluated and approved for ambulance transport services.
Medium impact
08.02.47, linvoseltamab-gcpt (Lynozyfic™)
Independence Blue Cross·Effective Oct 20, 2025
This is a new pharmacy policy effective 10/20/2025 for linvoseltamab-gcpt (Lynozyfic™), a recently FDA-approved bispecific antibody. The policy establishes coverage criteria, prior authorization requirements, and billing guidelines for this new oncology therapeutic agent. Billing teams must implement prior authorization protocols and ensure claims are submitted with appropriate diagnosis codes supporting medical necessity.
Medium impact
08.02.45, Telisotuzumab vedotin-tllv (Emrelis™)
Independence Blue Cross·Effective Oct 1, 2025
This is a new pharmacy policy for Telisotuzumab vedotin-tllv (Emrelis™), a new therapeutic agent. The policy establishes coverage, billing, and clinical guidelines for this medication effective October 1, 2025. The billing team must identify the specific HCPCS drug code and any associated prior authorization or documentation requirements once the full policy text is reviewed.
Medium impact
11.03.18, Endoscopic Submucosal Dissection (ESD)
Independence Blue Cross·Effective Oct 1, 2025
A new medical policy for Endoscopic Submucosal Dissection (ESD) has been established for commercial insurance plans. This policy will define coverage criteria, billing requirements, and potentially prior authorization rules for this specialized gastrointestinal procedure.
Medium impact
00.10.45, Reimbursement For Advanced Practice Provider Services
Independence Blue Cross·Effective Feb 1, 2026
A new policy (00.10.45) has been established governing reimbursement for Advanced Practice Provider (APP) services. This policy will define how nurse practitioners, physician assistants, and other APPs can bill for their services under commercial insurance plans.
Medium impact
00.01.61b, Reimbursement for Components of Comprehensive Laboratory Panels
Independence Blue Cross·Effective Feb 1, 2026
This policy updates reimbursement rules for components of comprehensive laboratory panels for commercial insurance plans. The change affects both coverage decisions and medical coding requirements for laboratory billing.

Browse by payer Browse by state Browse by specialty Browse by billing code Browse & filter all changes

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Archive by year

2023 2024 2025 2026

09.00.24c, Full-Body Computerized Tomography (CT) Scan Screening

07.03.15d, Evaluation and Management (E&M) of Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS)

11.08.05g, Application and Removal of Tattoos

11.05.07d, Surgical Correction of Strabismus

07.13.07l, Corneal Pachymetry Using Ultrasound

09.00.51a, Positron Emission Mammography (PEM)

11.06.06h, Magnetic Resonance Imaging (MRI)-Guided Focused Ultrasound Ablation

12.04.04b, Acute Care Facility Inpatient Transfers

05.00.47u, Knee Orthoses

05.00.39v, Ankle-Foot/Knee-Ankle-Foot Orthoses

11.14.21l, Microprocessor-Controlled Prostheses for Lower-Extremity Amputees

05.00.11l, Therapeutic Shoes and Orthopedic Shoes

08.01.13l, Brentuximab Vedotin (Adcetris®)

07.07.03n, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])

07.05.02t, Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders

08.01.21h, Blinatumomab (Blincyto®)

07.00.21k, Allergy Immunotherapy

11.07.01ac, Hematopoietic Stem Cell Transplantation

12.04.03d, Air Ambulance Services

12.04.02l, Ground Ambulance Services (Emergency and Nonemergency) (Independence)

08.02.47, linvoseltamab-gcpt (Lynozyfic™)

08.02.45, Telisotuzumab vedotin-tllv (Emrelis™)

11.03.18, Endoscopic Submucosal Dissection (ESD)

00.10.45, Reimbursement For Advanced Practice Provider Services

00.01.61b, Reimbursement for Components of Comprehensive Laboratory Panels